Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pt-richcore/Sn-richsubsurface/Ptskin nanocubes as highly active and stable electrocatalysts for the ethanol oxidation reaction

  • Rizo, Rubén
  • Arán-Ais, Rosa M.
  • Padgett, Elliot
  • Muller, David A.
  • Lázaro Elorri, María Jesús
  • Solla-Gullón, José
  • Feliu, Juan M.
  • Pastor Tejera, Elena
  • Abruña, Héctor D.
Nanocatalyst performance towards the ethanol oxidation reaction (EOR) for fuel cell applications can be enhanced by exploiting the benefits of structural and compositional sensitivity and control. We describe the synthesis and characterization of cubic Pt-Sn alloyed nanoparticles consisting of (100) faceted Pt-Sn nanoparticles with a core-shell structure, with a Pt-rich core and a Sn-rich shell. Stability tests indicated that this catalyst preserves its morphology and remains well-dispersed on the carbon support after 5,000 potential cycles, while a cubic (pure) Pt catalyst exhibited severe agglomeration of the nanoparticles after the same stability testing protocol. Analysis of the elemental distribution in the nanoparticles by STEM-EELS indicated that Sn dissolves from the outer part of the shell after potential cycling, forming a ~0.5 nm Pt skin. Finally, the activity of this bimetallic core-shell nanostructured electrocatalyst towards the EOR was investigated, exhibiting currents about three times higher than those of unshaped Pt-Sn nanoparticles and six times higher than Pt nanocubes., This work has been supported by Fundación Cajacanarias (project BIOGRAF), the Ministry of Economy and Competitiveness (MINECO) through the projects CTQ2011-28913-C02-02 and ENE2014-52158-C2-2-R (co-funded by FEDER) and the. The authors acknowledge the SEGAI services of Universidad de La Laguna for important technical assistance and R.R also thanks the funding received from MINECO (EEBB-I-16-11762) to carry out a predoctoral stay in a foreign R&D center. E.P. acknowledges support from an electron microscopy facilities supported by the NSF MRSEC program (DMR 1120296) and an NSF MRI grant (DMR 1429155).J.S.G. acknowledges financial support from VITC (Vicerrectorado de Investigación y Transferencia de Conocimiento) of the University of Alicante., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evidence for immunity to SARS-CoV-2 from epidemiological data series

  • Yubero, Pablo
  • Lavin, Alvar A.
  • Poyatos, Juan F.
The duration of immunity to SARS-CoV-2 is uncertain. Delineating immune memory typically requires longitudinal serological studies that track antibody prevalence in the same cohort for an extended time. However, this information is needed in faster timescales. Notably, the dynamics of an epidemic where recovered patients become immune for any period should differ significantly from those of one where the recovered promptly become susceptible. Here, we exploit this difference to provide a reliable protocol that can estimate immunity early in an epidemic. We verify this protocol with synthetic data, discuss its limitations, and then apply it to evaluate human immunity to SARS-CoV-2 in mortality data series from New York City. Our results indicate that New York's mortality figures are incompatible with immunity lasting anything below 105 or above 211 days (90% CI.), and set an example on how to assess immune memory in emerging pandemics before serological studies can be deployed., This work was supported by PhD fellowship BES-2016-079127 (P.Y.) and grant FIS2016-78781-R (J.F.P.) from the Spanish Ministerio de Economia y Competitividad and the European Social Fund., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hypoxia compromises the mitochondrial metabolism of Alzheimer’s disease microglia via HIF1

  • March Díaz, Rosana
  • Lara-Ureña, Nieves
  • Romero-Molina, Carmen
  • Heras-Garvin, Antonio
  • Ortega de San Luis, Clara
  • Álvarez-Vergara, María I.
  • Sánchez García, Manuel A.
  • Sánchez-Mejias, Elisabeth
  • Dávila, José C.
  • Rosales-Nieves, Alicia E.
  • Forja, Cristina
  • Navarro-Garrido, Victoria
  • Gómez-Arboledas, Ángela
  • Sánchez-Mico, María V.
  • Viehweger, Adrian
  • Gerpe, Almudena
  • Hodson, Emma J.
  • Vizuete, Marisa
  • Bishop, Tammie
  • Serrano-Pozo, Alberto
  • López-Barneo, José
  • Berra, Edurne
  • Vitorica, Javier
  • Pascual Bravo, Alberto
Genetic Alzheimer’s disease (AD) risk factors associate with reduced defensive amyloid β plaque-associated microglia (AβAM), but the contribution of modifiable AD risk factors to microglial dysfunction is unknown. In AD mouse models, we observe concomitant activation of the hypoxia-inducible factor 1 (HIF1) pathway and transcription of mitochondrial-related genes in AβAM, and elongation of mitochondria, a cellular response to maintain aerobic respiration under low nutrient and oxygen conditions. Overactivation of HIF1 induces microglial quiescence in cellulo, with lower mitochondrial respiration and proliferation. In vivo, overstabilization of HIF1, either genetically or by exposure to systemic hypoxia, reduces AβAM clustering and proliferation and increases Aβ neuropathology. In the human AD hippocampus, upregulation of HIF1α and HIF1 target genes correlates with reduced Aβ plaque microglial coverage and an increase of Aβ plaque-associated neuropathology. Thus, hypoxia (a modifiable AD risk factor) hijacks microglial mitochondrial metabolism and converges with genetic susceptibility to cause AD microglial dysfunction., R.M.-D. was the recipient of a Sara Borrell fellowship from Instituto de Salud Carlos III (ISCIII) (CD09/0007). N.L.-U., C.O.-d.S.L., C.R.-M. and M.I.A.-V. were the recipients of FPU fellowships from Spanish Ministry of Education, Culture and Sport (FPU14/02115, AP2010‐1598, FPU16/02050 and FPU15/02898, respectively). A.H.-G. was the recipient of an FPI fellowship from the Spanish Ministry of Education, Culture and Sport (BES-2010-033886). This work was supported by grants from the Spanish MINEICO, ISCIII and FEDER (European Union) (SAF2012‐33816, SAF2015‐64111‐R, SAF2017-90794-REDT and PIE13/0004 to A.P.); by the Regional Government of Andalusia co-funded by CEC and FEDER funds (European Union) (‘Proyectos de Excelencia’; P12‐CTS‐2138 and P12‐CTS‐2232 to A.P.); by the ‘Ayuda de Biomedicina 2018’, Fundación Domingo Martínez (to A.P.) ; by the ISCIII of Spain, co-financed by FEDER funds (European Union) through grants PI18/01556 (to J.V.) and PI18/01557 (to A. Gutierrez); by Junta de Andalucía, co-financed by FEDER funds (grants UMA18-FEDERJA-211 (to A. Gutierrez) and US‐1262734 (to J.V.)); and by Spanish MINEICO (BFU2016-76872-R and BES-2011-047721 to E.B.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocyte-neuron metabolic cooperation shapes brain activity

  • Bonvento, Gilles
  • Bolaños, Juan P.
The brain has almost no energy reserve, but its activity coordinates organismal function, a burden that requires precise coupling between neurotransmission and energy metabolism. Deciphering how the brain accomplishes this complex task is crucial to understand central facets of human physiology and disease mechanisms. Each type of neural cell displays a peculiar metabolic signature, forcing the intercellular exchange of metabolites that serve as both energy precursors and paracrine signals. The paradigm of this biological feature is the astrocyte-neuron couple, in which the glycolytic metabolism of astrocytes contrasts with the mitochondrial oxidative activity of neurons. Astrocytes generate abundant mitochondrial reactive oxygen species and shuttle to neurons glycolytically derived metabolites, such as L-lactate and L-serine, which sustain energy needs, conserve redox status, and modulate neurotransmitter-receptor activity. Conversely, early disruption of this metabolic cooperation may contribute to the initiation or progression of several neurological diseases, thus requiring innovative therapies to preserve brain energetics., G.B. received grants from the Centre National de la Recherche Scientifique (CNRS), the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Agence Nationale de la Recherche (ANR 2011 MALZ-0003 MetALZ; ANR-18-C816-0008-03 ADORASTrAU), Association France Alzheimer, Fondation de France (Prix Spécial 2012), Fondation Alzheimer, and Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences (NeurATRIS ANR-11-INBS-0011). J.P.B. is funded by the Agencia Estatal de Investigación (PID2019-105699RB-I00 / AEI / 10.13039/501100011033 and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), Junta de Castilla y León (CSI151P20 and Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA, and Fundación Ramón Areces.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant

  • Campos-Mata, Leire de
  • Trinité, Benjamin
  • Modrego, Andrea
  • Tejedor, Sonia
  • Pradenas, Edwards
  • Rodrigo Melero, Natalia
  • Carlero, Diego
  • Marfil, Silvia
  • Pons-Grífols, Anna
  • Bueno-Carrasco, M. Teresa
  • Santiago, César
  • Tarrés-Freixas, Ferrán
  • Urrea, Víctor
  • Izquierdo-Useros, Núria
  • Riveira-Muñoz, Eva
  • Ballana, Ester
  • Pérez, Mónica
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carolis, Carlo
  • Arranz, Rocío
  • Blanco, Julià
  • Magri, Giulian
In the present study we report the functional and structural characterization of 17T2, a new highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody (mAb) isolated from a convalescent COVID-19 individual infected during the first wave of the COVID-19 pandemic. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA memory B cell and developed as a human recombinant IgG1. Functional characterization revealed that 17T2 mAb has a high and exceptionally broad neutralizing activity against all SARS-CoV-2 spike variants tested, including BQ.1.1. Moreover, 17T2 mAb has in vivo prophylactic activity against Omicron BA.1.1 infection in K18-hACE2 transgenic mice. 3D reconstruction from cryogenic-electron microscopy (cryo-EM) showed that 17T2 binds the Omicron BA.1 spike protein with the RBD domains in up position and recognizes an epitope overlapping with the receptor binding motif, as it is the case for other structurally similar neutralizing mAbs, including S2E12. Yet, unlike S2E12, 17T2 retains its high neutralizing activity against all Omicron sublineages tested, probably due to a larger contact area with the RBD, which could confer a higher resilience to spike mutations. These results highlight the impact of small structural antibody changes on neutralizing performance and identify 17T2 mAb as a potential candidate for future therapeutic and prophylactic interventions., We acknowledge access to the cryo-EM CNB-CSIC facility in the context of the CRIOMECORR project (ESFRI-2019-01-CSIC-16) and we thank the staff of the Protein Technology Unity (CRG) for the help in protein production. This study was supported by the COVID-19 call grant from Generalitat de Catalunya, Department of Health (to GM), grant Miguel Servet research program (to GM), and partially funded by the crowdfunding initiative #joemcorono and the Fundació Glòria Soler (to JB). A.P-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Innovation in the Business Sector: Where There's a Will There's a Way. Managers’ Perception of Science and R&D and Firms’ Engagement in Innovation

  • Rey-Rocha, Jesús
  • González Bravo, María Isabel
  • López Navarro, Irene
Este artículo está sujeto a una licencia CC BY 4.0, This research considers the hypothesis that firms’ propensity to undertake innovation activities is linked to variables related to their perception of science, their appraisal of the benefits and risks of R&D investing, and their attitude towards the role science plays within the firm, besides their economic and structural characteristics. We explore an empirical approach to studying the implications of managers’ perceptions and attitudes towards science and R&D on firms’ engagement in innovation. Research is based on the survey ‘Scientific culture, perception and attitudes towards science and innovation in the business sector’. Results evidence that corporate innovation decisions are not just a matter of money, and confirms the combined effect of a firm’s economic characteristics and perception of science on innovation engagement. Results confirm that managers’ attitude towards science and R&D is related to firms’ commitment to innovation, suggesting that their attitudes and behaviour in relation to science and investment in R&D should be given a more prominent role in S&T and innovation studies and in developing models of innovation in the future. This study provides some important implications for the management of innovation in the business sector. It stresses that innovation is related with managers having a perception of science and R&D that paves the way for the allocation of a firm’s resources to activities oriented towards knowledge generation and innovation. The results obtained here are still important regarding the way to address possible initiatives aimed at encouraging innovation in the business sector, This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness (research project CSO2014-53293-R) and the Spanish Foundation for Science and Technology, FECYT (research project FCT-16-10889), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Connecting genomic and proteomic signatures of amyloid burden in the brain

  • Puerta, Raquel
  • de Rojas, Itziar
  • García-González, Pablo
  • Olivé-Roig, Claudia
  • Sotolongo-Grau, Oscar
  • García-Sánchez, Ainhoa
  • García-Gutiérrez, Fernando
  • Montrreal, Laura
  • Tartari, Juan Pablo
  • Sanabria, Ángela
  • Pytel, Vanesa
  • Lage, Carmen
  • Quintela, Ines
  • Aguilera, Nuria
  • Rodríguez-Rodríguez, Eloy
  • Alarcón-Martín, Emilio
  • Orellana, Adelina
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Pinol-Ripoll, Gerard
  • López de Munain, Adolfo
  • García-Alberca, José María
  • Royo, José Luis
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis Miguel
  • Corbatón Anchuelo, Arturo
  • Gómez-Garre, Dulcenombre
  • Martínez Larrad, María Teresa
  • Franco-Macias, Emilio
  • Mir, Pablo
  • Medina, Miguel
  • Sánchez-Valle, Raquel
  • Icardo, Oriol
  • Dols-Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Alegret, Montse
  • Valero, Sergi
  • Marquie, Marta
  • Boada, Mercè
  • Juan, Pascual
  • Sánchez Cavazos, José Enrique
  • Cabrera, Alfredo
  • Cano, Amanda
  • Ruiz, Agustín
preprint 42 páginas, 6 figuras, 2 tablas, Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER 'Una manera de hacer Europa') grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed